Lexicon's LX1032 Phase 2 Trial Shows Positive Results

Lexicon Pharmaceuticals announced positive, top-line proof-of-concept data from its Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate.

Biopharmaceutical company Lexicon Pharmaceuticals, Inc. announced positive, top-line proof-of-concept data from its Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate.

Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract. It is characterized by severe diarrhea and flushing episodes with long-term consequences including malnutrition, heart disease, and death. Symptoms of carcinoid syndrome have been linked to excess production of serotonin by metastatic tumor cells. Telotristat etiprate is designed to reduce serotonin production.